As Primate Research Drops in Europe, Overseas Options Appeal

A combination of public opposition, intense regulations, and rising costs in the EU make conditions in China and elsewhere attractive for studying monkeys.

Written byKatarina Zimmer
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: © ISTOCK, SEREGRAFF

The use of monkeys in European research has been steadily declining. For instance, approximately 6,000 were used in scientific procedures in the European Union (EU) in 2011, compared with nearly 10,000 in 2008—counting both academic and industrial research. Most recently, a UK government report noted the number of primate experiments had fallen for the third consecutive year.

Researchers suspect that a combination of increasing regulatory pressure, rising costs, and mounting disapproval among the public are responsible. Some countries, such as the Netherlands and Belgium, have even taken political measures to deliberately scale back on primate research.

China recognizes that it’s going to be a leader in primate research and I have no doubt that that’s going to be true.

“The consequence of this is [the risk] that a lot of this research will move abroad,” says Stefan Treue, director of the Cognitive Neuroscience Laboratory at the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies